Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
NYSE:NVTA

Invitae - NVTA Stock Forecast, Price & News

$2.78
-0.04 (-1.42%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.71
$2.81
50-Day Range
$2.03
$3.61
52-Week Range
$1.83
$18.50
Volume
1.41 million shs
Average Volume
10.30 million shs
Market Capitalization
$675.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.04

Invitae MarketRank™ Forecast

Analyst Rating
Hold
1.75 Rating Score
Upside/​Downside
189.3% Upside
$8.04 Price Target
Short Interest
Bearish
19.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.44mentions of Invitae in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.43) to ($1.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

663rd out of 1,044 stocks

Medical Laboratories Industry

20th out of 25 stocks

NVTA stock logo

About Invitae (NYSE:NVTA) Stock

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Stock News Headlines

Invitae (NYSE:NVTA) Shares Up 7.8%
Invitae (NYSE:NVTA) Stock Price Down 5.5%
Invitae (NYSE:NVTA) Lifted to Sell at StockNews.com
Why Shares of Invitae Rose 11% on Tuesday
Why Invitae Stock Is Crushing It Today
Invitae (NVTA) Q3 2022 Earnings Call Transcript
Is Invitae Stock a Buy Now?
Invitae (NYSE: NVTA) Share Price and News
Why Invitae Stock Is Jumping Today
See More Headlines
Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Company Calendar

Last Earnings
11/08/2022
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
3,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.04
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$2.80
Forecasted Upside/Downside
+189.3%
Consensus Rating
Hold
Rating Score (0-4)
1.75
Research Coverage
12 Analysts

Profitability

Net Income
$-379,010,000.00
Net Margins
-617.65%
Pretax Margin
-626.73%

Debt

Sales & Book Value

Annual Sales
$460.45 million
Book Value
$0.65 per share

Miscellaneous

Free Float
240,224,000
Market Cap
$675.26 million
Optionable
Optionable
Beta
1.59

Key Executives

  • Mr. Kenneth D. Knight (Age 61)
    Pres, CEO & Director
    Comp: $1M
  • Ms. Yafei Wen (Age 49)
    Chief Financial Officer
    Comp: $422.73k
  • Mr. Thomas R. BridaMr. Thomas R. Brida (Age 51)
    Gen. Counsel, Chief Compliance Officer & Sec.
    Comp: $425k
  • Dr. Robert L. Nussbaum M.D.Dr. Robert L. Nussbaum M.D. (Age 72)
    Chief Medical Officer
    Comp: $391.35k
  • Ms. Shelly D. GuyerMs. Shelly D. Guyer (Age 62)
    Chief Sustainability Officer
    Comp: $430.44k
  • Mr. Robert F. Werner (Age 49)
    Chief Accounting Officer & Principal Accounting Officer
  • Mr. Jackson J. Finks C.F.A.
    CFA, Director of Investor Relations & Strategic Fin.
  • Mr. Lee Bendekgey J.D. (Age 64)
    Chief Policy Officer
  • Glenn Medalle
    Head of Talent
  • Ms. Desarie French
    Chief Talent Officer













NVTA Stock - Frequently Asked Questions

Should I buy or sell Invitae stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 3 sell ratings and 9 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View NVTA analyst ratings
or view top-rated stocks.

What is Invitae's stock price forecast for 2023?

12 Wall Street research analysts have issued 1-year target prices for Invitae's stock. Their NVTA share price forecasts range from $2.80 to $18.00. On average, they anticipate the company's share price to reach $8.04 in the next twelve months. This suggests a possible upside of 189.3% from the stock's current price.
View analysts price targets for NVTA
or view top-rated stocks among Wall Street analysts.

How have NVTA shares performed in 2022?

Invitae's stock was trading at $15.27 at the beginning of the year. Since then, NVTA stock has decreased by 81.8% and is now trading at $2.78.
View the best growth stocks for 2022 here
.

When is Invitae's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NVTA earnings forecast
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) announced its earnings results on Tuesday, November, 8th. The medical research company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.17. The medical research company earned $133.54 million during the quarter, compared to analyst estimates of $132.80 million. Invitae had a negative net margin of 617.65% and a negative trailing twelve-month return on equity of 39.04%.

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.95%), Vanguard Group Inc. (8.90%), Sumitomo Mitsui Trust Holdings Inc. (7.34%), Fisher Asset Management LLC (1.30%), State of Michigan Retirement System (0.83%) and Polar Asset Management Partners Inc. (0.70%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends
.

How do I buy shares of Invitae?

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $2.78.

How much money does Invitae make?

Invitae (NYSE:NVTA) has a market capitalization of $675.26 million and generates $460.45 million in revenue each year. The medical research company earns $-379,010,000.00 in net income (profit) each year or ($13.84) on an earnings per share basis.

How many employees does Invitae have?

The company employs 3,000 workers across the globe.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (415) 374-7782 or via email at ir@invitae.com.

This page (NYSE:NVTA) was last updated on 11/27/2022 by MarketBeat.com Staff